180 related articles for article (PubMed ID: 27327285)
1. Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept.
Baisiwala S; Bundorf MK; Pershing S
Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6):555-62. PubMed ID: 27327285
[TBL] [Abstract][Full Text] [Related]
2. Physician-Industry Interactions and Anti-Vascular Endothelial Growth Factor Use Among US Ophthalmologists.
Taylor SC; Huecker JB; Gordon MO; Vollman DE; Apte RS
JAMA Ophthalmol; 2016 Aug; 134(8):897-903. PubMed ID: 27356110
[TBL] [Abstract][Full Text] [Related]
3. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
[TBL] [Abstract][Full Text] [Related]
4. High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States.
Erie JC; Barkmeier AJ; Hodge DO; Mahr MA
Ophthalmology; 2016 Jun; 123(6):1257-62. PubMed ID: 26976701
[TBL] [Abstract][Full Text] [Related]
5. Open Payments Database: Anti-Vascular Endothelial Growth Factor Agent Payments to Ophthalmologists.
Singh N; Chang JS; Rachitskaya AV
Am J Ophthalmol; 2017 Jan; 173():91-97. PubMed ID: 27697472
[TBL] [Abstract][Full Text] [Related]
6. Factors Associated With Poor Response to Aflibercept After Switching From Ranibizumab or Bevacizumab in Neovascular Age-related Macular Degeneration.
Cheng S; Leng T
Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):458-65. PubMed ID: 27183550
[TBL] [Abstract][Full Text] [Related]
7. Do published trial results influence physician prescribing patterns? Intravitreal antivascular endothelial growth factor usage by the United States Ophthalmologists before and after Protocol T study.
Shah S; Markatia Z; Watane A; Feldman A; Shah L; Sridhar J
Curr Opin Ophthalmol; 2023 May; 34(3):218-225. PubMed ID: 36866850
[TBL] [Abstract][Full Text] [Related]
8. Variation in Ophthalmologist Use of Antivascular Endothelial Growth Factor Therapy Among Medicare Beneficiaries.
Thakore RV; Greenberg PB; Behrens JJ; French DD
JAMA Ophthalmol; 2016 Sep; 134(9):1071-2. PubMed ID: 27366859
[No Abstract] [Full Text] [Related]
9. Use of Bevacizumab and Ranibizumab for Wet Age-Related Macular Degeneration: Influence of CATT Results and Introduction of Aflibercept.
Pershing S; Talwar N; Armenti ST; Grubbs J; Rosenthal JM; Dedania VS; Stein JD
Am J Ophthalmol; 2019 Nov; 207():385-394. PubMed ID: 31100217
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
12. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
Forooghian F; Albiani DA; Kirker AW; Merkur AB
Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
[TBL] [Abstract][Full Text] [Related]
13. Frequency of Bevacizumab and Ranibizumab Injections for Diabetic Macular Edema in Medicare Beneficiaries.
Wu CM; Wu AM; Greenberg PB; Yu F; Lum F; Coleman AL
Ophthalmic Surg Lasers Imaging Retina; 2018 Apr; 49(4):241-244. PubMed ID: 29664980
[TBL] [Abstract][Full Text] [Related]
14. An Analysis of Medicare Reimbursement to Ophthalmologists: Years 2012 to 2013.
Han E; Baisiwala S; Jain A; Bundorf MK; Pershing S
Am J Ophthalmol; 2017 Oct; 182():133-140. PubMed ID: 28784553
[TBL] [Abstract][Full Text] [Related]
15. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
[TBL] [Abstract][Full Text] [Related]
16. NONINFECTIOUS VITRITIS AFTER INTRAVITREAL INJECTION OF ANTI-VEGF AGENTS: Variations in Rates and Presentation by Medication.
Williams PD; Chong D; Fuller T; Callanan D
Retina; 2016 May; 36(5):909-13. PubMed ID: 27115856
[TBL] [Abstract][Full Text] [Related]
17. Association between Industry Payments and Anti-vascular Endothelial Growth Factor Use in Medicare Beneficiaries.
Mahr MA; Hodge DO; Erie JC
Ophthalmol Retina; 2017; 1(1):19-24. PubMed ID: 31047391
[TBL] [Abstract][Full Text] [Related]
18. Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients.
Hall LB; Zebardast N; Huang JJ; Adelman RA
J Ocul Pharmacol Ther; 2014 May; 30(4):346-52. PubMed ID: 24552305
[TBL] [Abstract][Full Text] [Related]
19. The Biosimilar Paradox: How Anti-Vascular Endothelial Growth Factor Biosimilars Could Increase Patient and Overall Health Care Costs.
Zhang C; Friedman S; Mruthyunjaya P; Parikh R
Ophthalmology; 2023 Sep; 130(9):966-972. PubMed ID: 37116720
[TBL] [Abstract][Full Text] [Related]
20. The Role of Anti-VEGF Therapy in the Treatment of Diabetic Macular Edema.
Moshfeghi DM; Kaiser PK; Michels S; Midena E; Kitchens JW; Prenner JL; Regillo CD; Reichel E
Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6 Suppl):S4-S14. PubMed ID: 27348433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
